title: Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention.
abstract: OBJECTIVE
  Our objective was to explore the effects of atorvastatin on changes of CD4+CD25+ regulatory T cells (Tregs), FoxP3 expression in the infarct-related coronary artery, and peripheral venous blood of patients with ST-segment elevation myocardial infarction.
  
  
  METHODS
  We recorded 112 cases of patients with ST-segment elevation myocardial infarction who were randomly assigned to receive either atorvastatin 80 mg (n = 52) or placebo (n = 60) before primary percutaneous coronary intervention. Blood samples were obtained from the infarct-related coronary artery and peripheral vein during percutaneous coronary intervention. The proportion of CD4+CD25+ Tregs, FoxP3 mRNA expression in blood and concentrations of transforming growth factor-β and interferon-γ in plasma of the samples were measured or detected by flow cytometry, real-time polymerase chain reaction, or enzyme-linked immunosorbent assay, respectively.
  
  
  RESULTS
  In comparison with the control group, the proportions of CD4+CD25+ Tregs and the mRNA level of FoxP3 and transforming growth factor-β significantly increased; however, interferon-γ decreased with atorvastatin therapy. In the controls, the proportions of CD4+CD25+ Tregs and the mRNA level of FoxP3 and transforming growth factor-β were significantly decreased, but the level of interferon-γ increased more in the infarct-related coronary artery than in the peripheral vein.
  
  
  CONCLUSIONS
  : The inhibition of CD4+CD25+ Tregs in patients with ST-segment elevation myocardial infarction could be regulated with atorvastatin given before percutaneous coronary intervention.
authors.affiliation: School of Medicine, Shandong University, Jinan, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.forename: Shaoqin
authors.initials: S
authors.lastname: Wang
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Guan
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Wenzhi
authors.initials: W
authors.lastname: Xie
authors.forename: Nan
authors.initials: N
authors.lastname: Li
authors.forename: Peng
authors.initials: P
authors.lastname: Zhao
authors.forename: Guohai
authors.initials: G
authors.lastname: Su
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000069059:Atorvastatin; D015704:CD4 Antigens / Q000276:immunology; D003331:Coronary Vessels / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D004562:Electrocardiography; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000096:biosynthesis*; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015704:CD4 Antigens; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D006538:Heptanoic Acids; C508017:IL2RA protein, human; D007155:Immunologic Factors; D053645:Interleukin-2 Receptor alpha Subunit; D011758:Pyrroles; D016212:Transforming Growth Factor beta; D007371:Interferon-gamma; D000069059:Atorvastatin